Most Read Articles
02 Nov 2019
Treatment with the selective serotonin reuptake inhibitor escitalopram may confer beneficial effects on neuroticism, possibly by inducing reduction in anxiety, a recent study has shown.
05 Nov 2019
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
5 days ago
Maribavir 400 mg twice daily appears to have comparable efficacy to valganciclovir at clearing cytomegalovirus viraemia in transplant recipients, a study has found.
4 days ago
Individuals with and without gout appear to have a similar risk of developing colorectal cancer, suggesting that gout does not contribute to a risk increase, a study has found.

Sorafenib-pravastatin combo does not improve survival in hepatocellular carcinoma

20 Aug 2019

The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.

A total of 312 patients with advanced HCC and who were naïve to systemic treatment were assigned to receive sorafenib either in combination with pravastatin (n=162; median age, 68 years; 96.3 percent male) or alone (n=161; median age, 68 years; 88.2 percent male). The primary study outcome was overall survival (OS), while progression-free survival (PFS), safety, time to treatment failure, quality of life and time to progression were secondary endpoints.

Patients who received the combination treatment survived for a median period of 34.7 months. This outcome was not significantly better than in those who were given sorafenib alone (median, 36.1 months).

A total of 269 deaths were reported, 135 of which occurred in the combination arm. The resulting OS rates were comparable between the two treatment arms (sorafenib alone vs combination: 44.9 percent vs 47.2 percent; hazard ratio [HR], 1.00, 95 percent CI, 0.79–1.28; p=0.975).

The same was true for 1-year PFS (16.5 percent vs 18.8 percent; HR, 1.00, 0.80–1.25; p=0.986), time to progression (28.3 percent vs 26.9 percent; HR, 1.06, 0.80–1.38; p=0.698) and time to treatment failure (19.3 percent vs 25.2 percent; HR, 0.92, 0.73–1.16; p=0.502).

Multivariate analysis further confirmed these findings, showing that only scores in the Cancer of Liver Italian Program were significant predictors of survival (HR, 2.54, 1.88–3.44; p<0.0001) and that the assigned treatment was not (HR, 0.94, 0.71–1.25; p=0.688).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Nov 2019
Treatment with the selective serotonin reuptake inhibitor escitalopram may confer beneficial effects on neuroticism, possibly by inducing reduction in anxiety, a recent study has shown.
05 Nov 2019
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
5 days ago
Maribavir 400 mg twice daily appears to have comparable efficacy to valganciclovir at clearing cytomegalovirus viraemia in transplant recipients, a study has found.
4 days ago
Individuals with and without gout appear to have a similar risk of developing colorectal cancer, suggesting that gout does not contribute to a risk increase, a study has found.